Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative.
Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the potential impact of President Donald Trump’s tariffs.
